{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:23Z","timestamp":1787009363196,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"H.W.V."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral RNA. We identified potent lipophilic small\u00a0interfering RNA (siRNA) conjugates targeting highly conserved regions of\u00a0SARS-CoV-2 outside of the spike-encoding region capable of achieving\u00a0\u22653-log viral reduction. Serial passaging studies demonstrated that a two-siRNA combination prevented development of resistance compared to a single\u00a0siRNA approach. Viral resistance to single siRNA treatment occurred due to emergence of point mutations at critical positions required for siRNA-mediated target binding and cleavage, which led to a loss of siRNA efficacy. With a two-siRNA combination, emergence of mutations within the siRNA binding site was abolished. When delivered intranasally, two-siRNA combination protected Syrian hamsters from weight loss and lung pathology by viral infection upon prophylactic administration but not following onset of infection. Together, the data support potential utility of RNAi as a prophylactic approach with high resistance barrier to counteract SARS-CoV-2 emergent variants and complement vaccination. Most importantly, given that the siRNAs can be rapidly developed from a new pathogen sequence, this strategy has implications as a new type of preventive medicine\u00a0that may protect against future coronavirus pandemics.<\/jats:p>","DOI":"10.1093\/nar\/gkae1195","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T15:22:38Z","timestamp":1731943358000},"source":"Crossref","is-referenced-by-count":10,"title":["High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination"],"prefix":"10.1093","volume":"53","author":[{"given":"Yesseinia I","family":"Anglero-Rodriguez","sequence":"first","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian A","family":"Lempp","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McIninch","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-608X","authenticated-orcid":false,"given":"Mark K","family":"Schlegel","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bohan","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wong","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6076-4035","authenticated-orcid":false,"given":"Christopher R","family":"Brown","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J","family":"Foster","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B","family":"Castoreno","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"Cuffe","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Montiel-Ruiz","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sahakyan","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana Shulga","family":"Morskaya","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D","family":"Barry","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Berman","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kasper","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Racie","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diann","family":"Weddle","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mobley","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wassarman","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bisbe","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-3032","authenticated-orcid":false,"given":"Ivan","family":"Zlatev","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlin","family":"Rogers","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Nechev","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Dybowski","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeho","family":"Chong","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5457-0604","authenticated-orcid":false,"given":"Jayaprakash","family":"Nair","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Simon","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Sloan","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Hwang","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert W","family":"Virgin","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]},{"name":"Department of Pathology and Immunology, Washington University School of Medicine , Saint Louis,\u00a0MO 63110 ,","place":["USA"]},{"name":"Department of Internal Medicine, UT Southwestern Medical Center , Dallas , TX 75390 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-0184","authenticated-orcid":false,"given":"Martin A","family":"Maier","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Hinkle","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M","family":"Hebner","sequence":"additional","affiliation":[{"name":"Vir Biotechnology Inc. ; San Francisco , CA 94158 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Akinc","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-0250","authenticated-orcid":false,"given":"Vasant","family":"Jadhav","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals ; Cambridge , MA 002142 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2025011110010314800_B1","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","article-title":"Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis","volume":"401","author":"Stein","year":"2023","journal-title":"Lancet"},{"key":"2025011110010314800_B5","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: a prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025011110010314800_B6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B7","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025011110010314800_B10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"2025011110010314800_B11","doi-asserted-by":"crossref","first-page":"e082650","DOI":"10.1002\/alz.082650","article-title":"Interim phase 1 part A results for ALN-APP, the first investigational RNAi therapeutic in development for Alzheimer's disease","volume":"19","author":"Cohen","year":"2023","journal-title":"Alzheimers Dementia"},{"key":"2025011110010314800_B12","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2025011110010314800_B13","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1021\/jacs.7b02694","article-title":"Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA","volume":"139","author":"Schlegel","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"2025011110010314800_B14","first-page":"203","article-title":"Solid-phase synthesis of siRNA oligonucleotides","volume":"11","author":"Beaucage","year":"2008","journal-title":"Curr. Opin. Drug. Discov. Devel."},{"key":"2025011110010314800_B15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2105-11-129","article-title":"RNAstructure: software for RNA secondary structure prediction and analysis","volume":"11","author":"Reuter","year":"2010","journal-title":"BMC Bioinf."},{"key":"2025011110010314800_B16","doi-asserted-by":"crossref","first-page":"30494","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494","article-title":"GISAID: global initiative on sharing all influenza data - from vision to reality","volume":"22","author":"Shu","year":"2017","journal-title":"Euro Surveill."},{"key":"2025011110010314800_B17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1471-2105-10-421","article-title":"BLAST+: architecture and applications","volume":"10","author":"Camacho","year":"2009","journal-title":"BMC Bioinf."},{"key":"2025011110010314800_B18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/nar\/gkf436","article-title":"MAFFT: a novel method for rapid multiple sequence alignment based on fast fourier transform","volume":"30","author":"Katoh","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"2025011110010314800_B19","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/bioinformatics\/bts578","article-title":"Adding unaligned sequences into an existing alignment using MAFFT and LAST","volume":"28","author":"Katoh","year":"2012","journal-title":"Bioinformatics"},{"key":"2025011110010314800_B20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/nar\/gkab1248","article-title":"Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread","volume":"50","author":"Ambike","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"2025011110010314800_B21","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"2025011110010314800_B22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2018.03.002","article-title":"Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers","volume":"153","author":"Musharrafieh","year":"2018","journal-title":"Antiviral Res."},{"key":"2025011110010314800_B23","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.jmb.2017.07.018","article-title":"Structural foundations of RNA silencing by Argonaute","volume":"429","author":"Sheu-Gruttadauria","year":"2017","journal-title":"J. Mol. Biol."},{"key":"2025011110010314800_B24","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2025011110010314800_B25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"2025011110010314800_B26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"2025011110010314800_B27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2025011110010314800_B28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"2025011110010314800_B29","doi-asserted-by":"crossref","first-page":"101992","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2021","journal-title":"iScience"},{"key":"2025011110010314800_B30","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"2025011110010314800_B31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"2025011110010314800_B32","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ymthe.2022.01.024","article-title":"Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV\/RNAi expression vectors","volume":"30","author":"Becker","year":"2022","journal-title":"Mol. Ther."},{"key":"2025011110010314800_B33","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/JVI.78.5.2601-2605.2004","article-title":"Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition","volume":"78","author":"Das","year":"2004","journal-title":"J. Virol."},{"key":"2025011110010314800_B34","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1093\/nar\/gkn109","article-title":"Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron","volume":"36","author":"Liu","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"2025011110010314800_B35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Micro."},{"key":"2025011110010314800_B36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"2025011110010314800_B37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025011110010314800_B38","doi-asserted-by":"crossref","first-page":"e2219523120","DOI":"10.1073\/pnas.2219523120","article-title":"Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection","volume":"120","author":"Hariharan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2025011110010314800_B39","first-page":"A1376","article-title":"A first-In-Human study of ARO-RAGE, A novel inhaled RNA-interference therapy for asthma","volume":"209","author":"O\u2019Carroll","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025011110010314800_B40","doi-asserted-by":"crossref","first-page":"e15298","DOI":"10.15252\/emmm.202115298","article-title":"A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant","volume":"14","author":"Chang","year":"2022","journal-title":"EMBO Mol. Med."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/53\/1\/gkae1195\/61002871\/gkae1195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nar\/article-pdf\/53\/1\/gkae1195\/61002871\/gkae1195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T05:01:30Z","timestamp":1736571690000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/doi\/10.1093\/nar\/gkae1195\/7919503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkae1195","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,13]]},"published":{"date-parts":[[2024,12,9]]},"article-number":"gkae1195"}}